<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>15030741</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Knobel, Hernando</dc:author>
<dc:author>Carmona, Alexia</dc:author>
<dc:author>Sorli, M Luisa</dc:author>
<dc:author>López-Colomés, José Luis</dc:author>
<dc:author>Pedro-Botet, Juan</dc:author>
<dc:author>Jericó, Carlos</dc:author>
<dc:description xml:lang="en">BACKGROUND AND OBJECTIVE Our goal was to assess the main characteristics of cardiovascular disease in HIV-infected patients on highly active antiretroviral therapy (HAART). PATIENTS AND METHOD Retrospective analysis of the clinico-epidemiological characteristics of 16 HIV-infected patients treated with HAART who had suffered a cardiovascular event from a 1,459 patients' cohort. RESULTS Clinical presentation of cardiovascular disease was an acute coronary syndrome in 12 cases, ischemic stroke in 2 and peripheral vascular disease in 2. Patients included in the study had a mean of 3.2 cardiovascular risk factors, smoking and low HDL levels being the more prevalent risk factors. Eight (50%, 95% CI, 25-75%) patients fulfilled the criteria of metabolic syndrome. The mean CD4 count was 548 x 10(6)/l. CONCLUSIONS HIV-infected patients on HAART ha-ve a high cardiovascular risk. A strict management of modifiable risk factors must be warranted in these patients.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2004 Mar 06 </dc:date>
<dc:title xml:lang="es">Enfermedad cardiovascular sintomática en pacientes infectados por el virus de la inmunodeficiencia humana que reciben tratamiento antirretroviral de gran actividad.</dc:title>
<dc:title xml:lang="en">[Cardiovascular disease in HIV-infected patients on highly active antiretroviral therapy].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
